BioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.

Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of $29 million for the quarter ended March 31, 2016.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.